---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-23-000055"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-08-30T23:59:59+00:00"
generated_at: "2026-06-11T01:58:55.934265+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics director Assaf Segal resigns effective August 28, 2023

## Summary
- Assaf Segal resigned from the Board of Elicio Therapeutics, effective immediately on August 28, 2023.
- Resignation follows his planned departure as CEO of Clal Biotechnology Industries, not due to any disagreement.
- No replacement named; the Board continues with remaining members.

## SEC filing metadata
- accession: 0001601485-23-000055
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-08-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000055/0001601485-23-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000055/angn-20230828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-23-000055
- JSON: https://secwatch.observer/filing/0001601485-23-000055.json
- Plain text: https://secwatch.observer/filing/0001601485-23-000055.txt

## Key facts
- Executive change
  Assaf Segal resigned as Director at Elicio Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 28, 2023, Assaf Segal submitted his resignation from the Board of Directors (the “Board”) of Elicio Therapeutics, Inc. (the “Company”), which resignation was effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000055/0001601485-23-000055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.